1. Home
  2. GGG vs BBIO Comparison

GGG vs BBIO Comparison

Compare GGG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Graco Inc.

GGG

Graco Inc.

N/A

Current Price

$89.19

Market Cap

14.6B

Sector

Industrials

ML Signal

N/A

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

N/A

Current Price

$74.32

Market Cap

15.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GGG
BBIO
Founded
1926
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.6B
15.3B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
GGG
BBIO
Price
$89.19
$74.32
Analyst Decision
Buy
Strong Buy
Analyst Count
4
23
Target Price
$95.25
$82.26
AVG Volume (30 Days)
789.0K
2.8M
Earning Date
01-01-0001
05-22-2026
Dividend Yield
1.33%
N/A
EPS Growth
9.22
N/A
EPS
3.08
N/A
Revenue
$2,236,604,000.00
$502,076,000.00
Revenue This Year
$6.81
$88.86
Revenue Next Year
$4.65
$74.11
P/E Ratio
$28.74
N/A
Revenue Growth
5.83
126.26
52 Week Low
$72.06
$28.33
52 Week High
$95.69
$84.94

Technical Indicators

Market Signals
Indicator
GGG
BBIO
Relative Strength Index (RSI) 40.58 58.30
Support Level $80.80 $70.65
Resistance Level $95.35 $79.56
Average True Range (ATR) 1.79 3.35
MACD -0.86 0.42
Stochastic Oscillator 32.97 85.65

Price Performance

Historical Comparison
GGG
BBIO

About GGG Graco Inc.

Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.2 billion in sales in 2025.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: